It is particularly common among older demographics, where skin becomes less effective at producing Vitamin D, or among people with darker complexions
Marcin Chwistek of Fox Chase Cancer Center, who was not involved in the studies, told The Guardian : GLP-1 receptor agonists have never been just glucose-lowering drugs
Among the teens he works with, psychotherapist John Puls said the pattern often follows a familiar progression
For context, heres how the most recent GLP-1 weight-loss drugs reached UK patients: Wegovy (semaglutide 2.4 mg): MHRA approval September 2021, NICE TA875 issued March 2023
It's NSF Certified for Sport, meaning it's been tested to ensure not just purity and potency, but also that it's free of substances banned in competitive sport